Insulin-like growth factor receptor type I as a target for cancer therapy

Frontiers in Bioscience - Scholar

Volumn 5 S, Issue 2, 2013, Pages 439-450

  Corvaia, Nathalie ^a   Beck, Alain ^a   Caussanel, Véronique ^a   Goetsch, Liliane ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antibodies; Biomarkers; Cancer; IGF IR; Review; Translational research; Tyrosine kinase inhibitors

Indexed keywords

CETUXIMAB; CIXUTUMUMAB; DALOTUZUMAB; FIGITUMUMAB; FLUORODEOXYGLUCOSE F 18; GANITUMAB; GEMCITABINE; IRINOTECAN; KI 67 ANTIGEN; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; ROBATUMUMAB; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADRENAL CORTEX CARCINOMA; ALPHA CHAIN; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CELL MOTILITY; CELL TRANSFORMATION; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DRUG INDUSTRY; DRUG INHIBITION; DRUG SAFETY; DRUG SCREENING; EWING SARCOMA; FIRST IN HUMAN STUDY; GAMMA RADIATION; GENE AMPLIFICATION; GENE MUTATION; GROWTH RETARDATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; RHABDOMYOSARCOMA; SEQUENCE HOMOLOGY; SKIN BIOPSY; TRANSGENIC MOUSE; TREATMENT PLANNING; TUMOR GROWTH; ULTRAVIOLET IRRADIATION; WILD TYPE; XENOGRAFT; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84883251999     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s382     Document Type: Review

References (109)

1. Ullrich, A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S.,& Chen E: Insulin-like growth factor I. receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity EMBO. J. 5, 2503-2512 (1986)
2. Yakar, S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B.,& LeRoith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. ProcNatlAcadSciU.S.A. 96, 7324-7329 (1999)
3. Schally, A.V., Varga J.L.,& Engel J.B: Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer NatClinPractEndocrinolMetab 4, 33-43 (2008)
4. Marron-Terada, P.G., Brzycki-Wessell M.A.,& Dahms N.M: The two mannose 6-phosphate binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor display different ligand binding properties J. Biol Chem 273, 22358-22366 (1998)
5. Osipo, C., Dorman S.,& Frankfater A: Loss of insulin-like growth factor II. receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I. and insulin receptors ExpCell Res 264, 388-396 (2001)
6. Soos, M.A.,Siddle K: Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I. receptors involving hybrids with insulin receptors Biochem J. 263, 553-563 (1989)
7. Treadway, J.L., Morrison B.D., Goldfine I.D.,& Pessin J.E: Assembly of insulin/insulin-like growth factor-1. hybrid receptors in vitro J. Biol Chem 264, 21450-21453 (1989)
8. Siddle, K., Soos M.A., Field C.E.,& Nave B.T: Hybrid and atypical insulin/insulin-like growth factor I. receptors HormRes 41, 56-64 (1994)
9. Denley, A., Wallace J.C., Cosgrove L.J.,& Forbes B.E: The insulin receptor isoform exon 11-(IR-A). in cancer and other diseases: a review HormMetab Res 35, 778-785 (2003)
10. Sciacca, L., Prisco M., Wu A., Belfiore A., Vigneri R.,& Baserga R: Signaling differences from the A. and B. isoforms of the insulin receptor (IR). in 32D. cells in the presence or absence of IR. substrate-1. Endocrinology 144, 2650-2658 (2003)
11. Frasca, F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., Goldfine I.D., Belfiore A.,& Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II. receptor in fetal and cancer cells MolCell Biol 19, 3278-3288 (1999)
12. Soos, M.A., Field C.E.,& Siddle K: Purified hybrid insulin/insulin-like growth factor-I. receptors bind insulin-like growth factor-I, but not insulin, with high affinity Biochem J. 290, 419-426 (1993)
13. Frattali, A.L.,Pessin J.E: Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1. hybrid receptors J. Biol Chem 268, 7393-7400 (1993)
14. Belfiore, A: The role of insulin receptor isoforms and hybrid insulin/IGF-I. receptors in human cancer CurrPharmDes 13, 671-686 (2007)
15. Kato, H., Faria T.N., Stannard B., Roberts C.T., Jr,& LeRoith D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I). receptor Characterization of kinase-deficient IGF-I. receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J. Biol Chem 268, 2655-2661 (1993)
16. Favelyukis, S., Till J.H., Hubbard S.R.,& Miller W.T: Structure and autoregulation of the insulin-like growth factor 1. receptor kinase Nat Struct Biol 8, 1058-1063 (2001)
17. Kato, H., Faria T.N., Stannard B., Roberts C.T., Jr,& LeRoith D: Essential role of tyrosine residues 1131, 1135, and 1136. of the insulin-like growth factor-I (IGF-I). receptor in IGF-I. action MolEndocrinol 8, 40-50 (1994)
18. Navarro, M.,Baserga R: Limited redundancy of survival signals from the type 1. insulin-like growth factor receptor Endocrinology 142, 1073-1081 (2001)
19. Samani, A.A., Yakar S., LeRoith D.,& Brodt P: The role of the IGF. system in cancer growth and metastasis: overview and recent insights EndocrRev 28, 20-47 (2007)
20. Siddle, K., Urso B., Niesler C.A., Cope D.L., Molina L., Surinya K.H.,& Soos M.A: Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors BiochemSocTrans 29, 513-525 (2001)
21. Liu, J.P., Baker J., Perkins A.S., Robertson E.J.,& Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1). and type 1. IGF. receptor (Igf1r). Cell 75, 59-72 (1993)
22. Bateman, J.M.,McNeill H: Insulin/IGF. signalling in neurogenesis Cell MolLife Sci 63, 1701-1705 (2006)
23. Mathews, L.S., Hammer R.E., Behringer R.R., D'Ercole A.J., Bell G.I., Brinster R.L.,& Palmiter R.D: Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123, 2827-2833 (1988)
24. Baserga, R., Hongo A., Rubini M., Prisco M.,& Valentinis B: The IGF-I. receptor in cell growth, transformation and apoptosis BiochimBiophysActa 1332, F105-F126 (1997)
25. Xie, Y., Skytting B., Nilsson G., Brodin B.,& Larsson O: Expression of insulin-like growth factor-1. receptor in synovial sarcoma: association with an aggressive phenotype Cancer Res 59, 3588-3591 (1999)
26. Ouban, A., Muraca P., Yeatman T.,& Coppola D: Expression and distribution of insulin-like growth factor-1. receptor in human carcinomas HumPathol 34, 803-808 (2003)
27. Khandwala, H.M., McCutcheon I.E., Flyvbjerg A.,& Friend K.E: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth EndocrRev 21, 215-244 (2000)
28. Hankinson, S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E.,& Pollak M: Circulating concentrations of insulin-like growth factor-I. and risk of breast cancer Lancet 351, 1393-1396 (1998)
29. Chan, J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H.,& Pollak M: Plasma insulin-like growth factor-I. and prostate cancer risk: a prospective study Science 279, 563-566 (1998)
30. Yu, H., Spitz M.R., Mistry J., Gu J., Hong W.K.,& Wu X: Plasma levels of insulin-like growth factor-I. and lung cancer risk: a case-control analysis J.NatlCancer Inst 91, 151-156 (1999)
31. Ma, J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H.,& Stampfer M.J: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I. and IGF-binding protein-3. J.NatlCancer Inst 91, 620-625 (1999)
32. Baserga, R., Peruzzi F.,& Reiss K: The IGF-1. receptor in cancer biology Int J. Cancer 107, 873-877 (2003)
33. Sell, C., Rubini M., Rubin R., Liu J.P., Efstratiadis A.,& Baserga R: Simian virus 40. large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1. insulin-like growth factor receptor ProcNatlAcadSciU.S.A. 90, 11217-11221 (1993)
34. Sell, C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A.,& Baserga R: Effect of a null mutation of the insulin-like growth factor I. receptor gene on growth and transformation of mouse embryo fibroblasts MolCell Biol 14, 3604-3612 (1994)
35. DiGiovanni, J., Kiguchi K., Frijhoff A., Wilker E., Bol D.K., Beltran L., Moats S., Ramirez A., Jorcano J.,& Conti C: Deregulated expression of insulin-like growth factor 1. in prostate epithelium leads to neoplasia in transgenic mice ProcNatlAcadSciU.S.A. 97, 3455-3460 (2000)
36. Kulik, G., Klippel A.,& Weber M.J: Antiapoptotic signalling by the insulin-like growth factor I. receptor, phosphatidylinositol 3-kinase, and Akt MolCell Biol 17, 1595-1606 (1997)
37. D'Ambrosio, C., Valentinis B., Prisco M., Reiss K., Rubini M.,& Baserga R: Protective effect of the insulin-like growth factor I. receptor on apoptosis induced by okadaic acid Cancer Res 57, 3264-3271 (1997)
38. Wu, Y., Tewari M., Cui S.,& Rubin R: Activation of the insulin-like growth factor-I. receptor inhibits tumor necrosis factor-induced cell death J.Cell Physiol 168, 499-509 (1996)
39. Harrington, E.A., Bennett M.R., Fanidi A.,& Evan G.I: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines EMBO. J. 13, 3286-3295 (1994)
40. Resnicoff, M., Coppola D., Sell C., Rubin R., Ferrone S.,& Baserga R: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1. insulin-like growth factor receptor Cancer Res 54, 4848-4850 (1994)
41. O'Connor, R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G.I., Baserga R.,& Blattler W.A: Identification of domains of the insulin-like growth factor I. receptor that are required for protection from apoptosis MolCell Biol 17, 427-435 (1997)
42. Resnicoff, M., Abraham D., Yutanawiboonchai W., Rotman H.L., Kajstura J., Rubin R., Zoltick P.,& Baserga R: The insulin-like growth factor I. receptor protects tumor cells from apoptosis in vivo Cancer Res 55, 2463-2469 (1995)
43. Lopez, T.,Hanahan D: Elevated levels of IGF-1. receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis Cancer Cell 1, 339-353 (2002)
44. Hazan, R.B., Qiao R., Keren R., Badano I.,& Suyama K: Cadherin switch in tumor progression AnnN.Y.AcadSci 1014, 155-163 (2004)
45. Zhang, D., Samani A.A.,& Brodt P: The role of the IGF-I. receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis HormMetab Res 35, 802-808 (2003)
46. Sachdev, D., Hartell J.S., Lee A.V., Zhang X.,& Yee D: A. dominant negative type I. insulin-like growth factor receptor inhibits metastasis of human cancer cells J. Biol Chem 279, 5017-5024 (2004)
47. Dunn, S.E., Ehrlich M., Sharp N.J., Reiss K., Solomon G., Hawkins R., Baserga R.,& Barrett J.C: A. dominant negative mutant of the insulin-like growth factor-I. receptor inhibits the adhesion, invasion, and metastasis of breast cancer Cancer Res 58, 3353-3361 (1998)
48. Albanell, J.,Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I. receptor, a new suspect J.NatlCancer Inst 93, 1830-1832 (2001)
49. Lu, Y., Zi X., Zhao Y., Mascarenhas D.,& Pollak M: Insulin-like growth factor-I. receptor signaling and resistance to trastuzumab (Herceptin). J.NatlCancer Inst 93, 1852-1857 (2001)
50. Guix, M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L.,& Engelman J.A: Acquired resistance to EGFR. tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins J.ClinInvest 118, 2609-2619 (2008)
51. Goetsch, L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F.,& Corvaia N: A. recombinant humanized anti-insulin-like growth factor receptor type I. antibody (h7C10). enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts Int J. Cancer 113, 316-328 (2005)
52. Slomiany, M.G., Black L.A., Kibbey M.M., Day T.A.,& Rosenzweig S.A: IGF-1. induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma BiochemBiophysResCommun 342, 851-858 (2006)
53. Jiang, Y., Rom W.N., Yie T.A., Chi C.X.,& Tchou-Wong K.M: Induction of tumor suppression and glandular differentiation of A549. lung carcinoma cells by dominant-negative IGF-I. receptor Oncogene 18, 6071-6077 (1999)
54. Chernicky, C.L., Yi L., Tan H., Gan S.U.,& Ilan J: Treatment of human breast cancer cells with antisense RNA. to the type I. insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo Cancer Gene Ther 7, 384-395 (2000)
55. Resnicoff, M: Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I. receptor (review). IntJ.MolMed 1, 883-888 (1998)
56. Andrews, D.W., Resnicoff M., Flanders A.E., Kenyon L., Curtis M., Merli G., Baserga R., Iliakis G.,& Aiken R.D: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I. receptor in malignant astrocytomas J. Clin Oncol 19, 2189-2200 (2001)
57. Arteaga, C.L.,Osborne C.K: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I. somatomedin receptor Cancer Res 49, 6237-6241 (1989)
58. Maloney, E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.M., Blattler W.A., Chittenden T.,& Singh R: An anti-insulin-like growth factor I. receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Res 63, 5073-5083 (2003)
59. Hailey, J., Maxwell E., Koukouras K., Bishop W.R., Pachter J.A.,& Wang Y: Neutralizing antiinsulin-like growth factor receptor 1. antibodies inhibit receptor function and induce receptor degradation in tumor cells MolCancer Ther 1, 1349-1353 (2002)
60. Zia, F., Jacobs S., Kull F., Jr, Cuttitta F., Mulshine J.L.,& Moody T.W: Monoclonal antibody alpha IR-3. inhibits non-small cell lung cancer growth in vitro and in vivo J.Cell BiochemSuppl 24, 269-275 (1996)
61. Yin, D., Vreeland F., Schaaf L.J., Millham R., Duncan B.A.,& Sharma A: Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy ClinCancer Res 13, 1000-1009 (2007)
62. Durai, R., Yang S.Y., Sales K.M., Seifalian A.M., Goldspink G.,& Winslet M.C: Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4. gene delivered locally by gene transfer Colorectal Dis 9, 625-631 (2007)
63. Garber, K: IGF-1: old growth factor shines as new drug target J. NatlCancer Inst 97, 790-792 (2005)
64. Avnet, S., Sciacca L., Salerno M., Gancitano G., Cassarino M.F., Longhi A., Zakikhani M., Carboni J.M., Gottardis M., Giunti A., Pollak M., Vigneri R.,& Baldini N: Insulin receptor isoform A. and insulin-like growth factor II. as additional treatment targets in human osteosarcoma Cancer Res 69, 2443-2452 (2009)
65. Haluska, P., Shaw H.M., Batzel G.N., Yin D., Molina J.R., Molife L.R., Yap T.A., Roberts M.L., Sharma A., Gualberto A., Adjei A.A.,& de Bono J.S: Phase I. dose escalation study of the anti insulin-like growth factor-I. receptor monoclonal antibody CP-751,871. in patients with refractory solid tumors Clin Cancer Res 13, 5834-5840 (2007)
66. Sachdev, D., Singh R., Fujita-Yamaguchi Y.,& Yee D: Down-regulation of insulin receptor by antibodies against the type I. insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer Cancer Res 66, 2391-2402 (2006)
67. Burtrum, D., Zhu Z., Lu D., Anderson D.M., Prewett M., Pereira D.S., Bassi R., Abdullah R., Hooper A.T., Koo H., Jimenez X., Johnson D., Apblett R., Kussie P., Bohlen P., Witte L., Hicklin D.J.,& Ludwig D.L: A. fully human monoclonal antibody to the insulin-like growth factor I. receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63, 8912-8921 (2003)
68. Schnitzer, T., Kuenkele K.P., Rebers F., Van Vugt M., Klein C., Lanzendoerfer M., Mundigl O., Parren P.W.H.I., van de Winkel J.G.J.,& Schumacher R: 214. POSTER. Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1. receptor European Journal of Cancer Supplements 4, 66-67 (2006)
69. 69Beltran,PJ, Mitchell,P, Moody,G, Lu,J, Chung,Y, Zhang,X, Freeman,D, Kendall,RL, Calzone,FJ, and Radinsky,R. AMG-479, a fully human anti IGF-1. receptor antibody, inhibits PI3K/Akt signaling and exerts potent antitumor effects in combination with EGF-R. inhibitors in pancreatic xenograft models Presented at: 2007. Gastrointestinal Cancers Symposium Orlando (Fl-. USA),
70. Wang, Y., Hailey J., Williams D., Wang Y., Lipari P., Malkowski M., Wang X., Xie L., Li G., Saha D., Ling W.L., Cannon-Carlson S., Greenberg R., Ramos R.A., Shields R., Presta L., Brams P., Bishop W.R.,& Pachter J.A: Inhibition of insulin-like growth factor-I. receptor (IGF-IR). signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR. antibody MolCancer Ther 4, 1214-1221 (2005)
71. Loo, D., Pryer N., Young P., Liang T., Coberly S., King K.L., Kang K., Roberts P., Tsao M., Xu X., Potts B.,& Mather J.P: The glycotope-specific RAV12. monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo MolCancer Ther 6, 856-865 (2007)
72. Cohen, B.D., Baker D.A., Soderstrom C., Tkalcevic G., Rossi A.M., Miller P.E., Tengowski M.W., Wang F., Gualberto A., Beebe J.S.,& Moyer J.D: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1. insulinlike growth factor receptor monoclonal antibody CP-751,871. ClinCancer Res 11, 2063-2073 (2005)
73. Hariharan, K., Dong J., Demarest S., Joseph I., Chu P., Graff C., Glaser S., Kramer-Stickland K., Peach R.,& Reff M: BIIB022, a fully human nonglycosylated {gamma}4P. antibody targeting IGF-1R. for cancer therapy AACR. Meeting Abstracts 2007, B210 (2007)
74. Kurmasheva, R., Boltz C., Phelps D., Morton C.,& Houghton P: Combination of CP-751871, a human monoclonal antibody against the IGF-1. receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas AACR. Meeting Abstracts 2007, C172 (2007)
75. Cao, L., Yu Y., Darko I., Currier D., Mayeenuddin L.H., Wan X., Khanna C.,& Helman L.J: Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT. pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody Cancer Res 68, 8039-8048 (2008)
76. Allen, G.W., Saba C., Armstrong E.A., Huang S.M., Benavente S., Ludwig D.L., Hicklin D.J.,& Harari P.M: Insulin-like growth factor-I. receptor signaling blockade combined with radiation Cancer Res 67, 1155-1162 (2007)
77. Wurch, T., Pandini G., Akla B., Corvaia N., Belfiore A.,& Goetsch L: 195. POSTER. In vitro and in vivo inhibition of functional responses at insulinlike growth factor-1/insulin hybrid receptors by h7C10, a novel humanized anti-IGF-1R. monoclonal antibody European Journal of Cancer Supplements 4, 61-61 (2006)
78. Gao, J.F., Chang YS. FAU.-. Jallal B., Jallal B.F.,& Viner J: Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology 79. Pollak, M: The insulin and insulin-like growth factor receptor family in neoplasia: an update NatRevCancer 12, 159-169 (2012)
79. Broussas, M., Dupont J., Gonzalez A., Blaecke A., Fournier M., Corvaia N.,& Goetsch L: Molecular mechanisms involved in activity of h7C10, a humanised monoclonal antibody to IGF-1. receptor Int J. Cancer Submitted (2008)
80. Atzori, F., Tabernero J., Cervantes A., Botero M., Hsu K., Brown H., Hanley W., Macarulla T., Rosello S.,& Baselga J: A. phase I, pharmacokinetic (PK). and pharmacodynamic (PD). study of weekly (qW). MK-0646, an insulin-like growth factor-1. receptor (IGF1R). monoclonal antibody (MAb). in patients (pts). with advanced solid tumors ASCO. Meeting Abstracts 26, 3519 (2008)
81. 82Watkins, D.J., J. Tabernero, H. Schmoll, T. Trarbach, F.J. Ramos, J. Howe, H.M. Brown, J. Clark, K. Hsu, B.D. Lu, & D. Cunningham: A. randomized phase II/III. study of the anti-IGF-1R. antibody MK-0646 (dalotuzumab). in combination with cetuximab (Cx). and irinotecan (Ir). in the treatment of chemorefractory metastatic colorectal cancer (mCRC). with wild-type (wt). KRAS. status J. Clin Oncol (Meeting Abstracts). 29, 3501 (2011).
82. Leong, S., Gore L., Benjamin R., Warren T., Eckhardt S.G., Camidge D.R., Dias C., Greig G., Frankel S.,& Kurzrock R: A. phase I. study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor). antagonist given weekly in patients with advanced solid tumors AACR. Meeting Abstracts 2007, A78 (2007)
83. Seraj, J., Tsai M., Seiberling M.,& Cutler D: Evaluation of safety and pharmacokinetics of a fully human IGF-1. receptor antibody, SCH. 717454, in healthy volunteers AACR. Meeting Abstracts 2007, A72 (2007)
84. Higano, C., LoRusso P., Gordon M., Yu E., Whiting S., Fox F., Katz T., Rowinsky E.,& Youssoufian H: A. phase I. study of the recombinant human IgG1. anti-IGF-IR. monoclonal antibody (Mab). IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis AACR. Meeting Abstracts 2007, B19 (2007)
85. Rothenberg, M., Poplin E., Sandler A., Rubin E., Fox F., Schwartz J., Vermeulen W.,& Youssoufian H: Phase I. dose-escalation study of the anti-IGF-IR. recombinant human IgG1. monoclonal antibody (Mab). IMC-A12, administered every other week to patients with advanced solid tumors AACR. Meeting Abstracts 2007, C84 (2007)
86. Rodon, J., Patnaik A., Stein M., Tolcher A., Ng C., Dias C., Greig G., Frankel S., Kurzrock R.,& Rubin E: A. phase I. study of q3W. R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor). antagonist in patients with advanced solid tumors AACR. Meeting Abstracts 2007, A77 (2007)
87. Tolcher, A.W., Rothenberg M.L., Rodon J., Delbeke D., Patnaik A., Nguyen L., Young F., Hwang Y., Haqq C.,& Puzanov I: A. phase I. pharmacokinetic and pharmacodynamic study of AMG. 479, a fully human monoclonal antibody against insulin-like growth factor type 1. receptor (IGF-1R), in advanced solid tumors ASCO. Meeting Abstracts 25, 3002 (2007)
88. Moody, G., Mitchell P., Cajulis E., Chung Y.A., Gyuris T., Juan T., Radinsky R., Calzone F.,& Beltran P: AMG. 479, a fully human anti IGF-1. receptor monoclonal antibody, is efficacious against Ewing's sarcoma and osteosarcoma xenografts AACR. Meeting Abstracts 2007, A64 (2007)
89. Scotlandi, K., Manara M.C., Nicoletti G., Lollini P.L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garcia-Echeverria C., Hofmann F.,& Picci P: Antitumor activity of the insulin-like growth factor-I. receptor kinase inhibitor NVP-AEW541. in musculoskeletal tumors Cancer Res 65, 3868-3876 (2005)
90. Scotlandi, K., Benini S., Nanni P., Lollini P.L., Nicoletti G., Landuzzi L., Serra M., Manara M.C., Picci P.,& Baldini N: Blockage of insulin-like growth factor-I. receptor inhibits the growth of Ewing's sarcoma in athymic mice Cancer Res 58, 4127-4131 (1998)
91. Sharma, S.V., Bell D.W., Settleman J.,& Haber D.A: Epidermal growth factor receptor mutations in lung cancer NatRevCancer 7, 169-181 (2007)
92. Karapetis, C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J.,& Zalcberg J.R: K-ras mutations and benefit from cetuximab in advanced colorectal cancer N.EnglJ.Med 359, 1757-1765 (2008)
93. Linardou, H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A.,& Murray S: Assessment of somatic k-RAS. mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol (2008)
94. Milano, G., Etienne-Grimaldi, M. C., Dahan, L., Francoual, M., Spano, J. P., Benchimol, D., Chazal, M., Letoublon, C., Andre, T., Gilly, F. N., Delpero, J. R., and Formento, J. L: Epidermal growth factor receptor (EGFR). status and K-Ras mutations in colorectal cancer AnnOncol 19. 2033-2038 (2008)
95. Pandini, G., Wurch T., Akla B., Corvaia N., Belfiore A.,& Goetsch L: Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1). receptor and insulin/IGF-1. hybrid receptors EurJ. Cancer 43, 1318-1327 (2007)
96. Haluska, P., Carboni J.M., TenEyck C., Attar R.M., Hou X., Yu C., Sagar M., Wong T.W., Gottardis M.M.,& Erlichman C: HER. receptor signaling confers resistance to the insulin-like growth factor-I. receptor inhibitor, BMS-536924. MolCancer Ther 7, 2589-2598 (2008)
97. Hollier, B.G., Kricker J.A., Van Lonkhuyzen D.R., Leavesley D.I.,& Upton Z: Substrate-bound insulin-like growth factor (IGF)-I-IGF. binding protein-vitronectinstimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT. pathway by alphav-integrins and the IGF-I. receptor Endocrinology 149, 1075-1090 (2008)
98. Canonici, A., Steelant W., Rigot V., Khomitch-Baud A., Boutaghou-Cherid H., Bruyneel E., Van Roy F., Garrouste F., Pommier G.,& Andre F: Insulin-like growth factor-I. receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin Int J. Cancer 122, 572-582 (2008)
99. Byron, S.A., Horwitz K.B., Richer J.K., Lange C.A., Zhang X.,& Yee D: Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells Br J. Cancer 95, 1220-1228 (2006)
100. Baserga, R: The insulin receptor substrate-1: A. biomarker for cancer?. ExpCell Res 315, 727-732 (2008)
101. Deevi, D., Burtrum D., Melchior M., Witte L., Ludwig D.L.,& Tonra J.R: 516. POSTER. Efficacy of EGFR. and IGF-1R. antibody therapy is independent of PTEN. status in a selection of tumor models European Journal of Cancer Supplements 6, 164-164 (2008)
102. Deevi, D., Huiling L., Ludwig D.L., Zhenping Z., Witte L.,& Tonra J: 87. POSTER. Correlation analysis utilizing measurements of tumor biomarkers and antibody efficacy against EGFR, IGF1R. and VEGFR2. receptors in multiple tumor models European Journal of Cancer Supplements 6, 30-30 (2008)
103. Sachdev, D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S.,& Yee D: A. chimeric humanized single-chain antibody against the type I. insulin-like growth factor (IGF). receptor renders breast cancer cells refractory to the mitogenic effects of IGFI. Cancer Res 63, 627-635 (2003)
104. Wu, J.D., Odman A., Higgins L.M., Haugk K., Vessella R., Ludwig D.L.,& Plymate S.R: In vivo effects of the human type I. insulin-like growth factor receptor antibody A12. on androgen-dependent and androgen-independent xenograft human prostate tumors ClinCancer Res 11, 3065-3074 (2005)
105. Lee, S.H., Li C., Zha J., Batson J., Tien J., Ross S., Reyes A., Deng R., Wang A., Stephan J.P., Damico L., Fielder P., Manning W.,& Xiang H: Understanding pharmacokinetics and pharmacodynamics relationship of anti-IGF1R. antibody in vivo AACR. Meeting Abstracts 2008, 3017 (2008)
106. Lacy, M.Q., Alsina M., Fonseca R., Paccagnella M.L., Melvin C.L., Yin D., Sharma A., Enriquez S.M., Pollak M., Jagannath S., Richardson P.,& Gualberto A: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1. Receptor monoclonal antibody CP-751,871. in patients with multiple myeloma J. Clin Oncol 26, 3196-3203 (2008)
107. de Bono, J.S., Attard G., Adjei A., Pollak M.N., Fong P.C., Haluska P., Roberts L., Melvin C., Repollet M., Chianese D., Connely M., Terstappen L.W.,& Gualberto A: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I. receptor Clin Cancer Res 13, 3611-3616 (2007)
108. Dinchuk JE. FAU.-. Cao, C., Cao C.F., Huang F.F., Reeves KA. FAU.-. Wang J., Wang J.F., Myers F.F., Cantor GH. FAU.-. Zhou X., Zhou X.F., Attar RM. FAU.-. Gottardis M., Gottardis M.F.,& Carboni J.M: Insulin receptor (IR). pathway hyperactivity in IGF-IR. null cells and suppression of downstream growth signaling using the dual IGF-IR/IR. inhibitor, BMS-754807
109. Huang, F., Hurlburt W., Greer A., Reeves K.A., Hillerman S., Chang H., Fargnoli J., Graf F.F., Gottardis M.M.,& Carboni J.M: Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model Cancer Res 70, 7221-7231 (2010)